Free Trial

Insmed (INSM) Competitors

Insmed logo
$165.31 -2.60 (-1.55%)
Closing price 04:00 PM Eastern
Extended Trading
$165.50 +0.19 (+0.11%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INSM vs. SNY, GSK, ARGX, TAK, ONC, BNTX, TEVA, GMAB, SMMT, and ASND

Should you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Sanofi (SNY), GSK (GSK), argenex (ARGX), Takeda Pharmaceutical (TAK), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.

Insmed vs. Its Competitors

Insmed (NASDAQ:INSM) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Sanofi has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insmed$363.71M96.07-$913.77M-$5.71-28.95
Sanofi$44.46B2.74$6.02B$4.1611.94

Sanofi has a net margin of 21.47% compared to Insmed's net margin of -259.82%. Sanofi's return on equity of 16.86% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Insmed-259.82% -195.37% -49.49%
Sanofi 21.47%16.86%9.63%

In the previous week, Insmed had 2 more articles in the media than Sanofi. MarketBeat recorded 18 mentions for Insmed and 16 mentions for Sanofi. Insmed's average media sentiment score of 0.95 beat Sanofi's score of 0.91 indicating that Insmed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Insmed
12 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Sanofi
8 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Insmed presently has a consensus price target of $152.88, indicating a potential downside of 7.52%. Sanofi has a consensus price target of $62.67, indicating a potential upside of 26.19%. Given Sanofi's stronger consensus rating and higher probable upside, analysts clearly believe Sanofi is more favorable than Insmed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insmed
1 Sell rating(s)
1 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86
Sanofi
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.00

Insmed has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

14.0% of Sanofi shares are held by institutional investors. 3.0% of Insmed shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Sanofi beats Insmed on 11 of the 17 factors compared between the two stocks.

Get Insmed News Delivered to You Automatically

Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INSM vs. The Competition

MetricInsmedMED IndustryMedical SectorNASDAQ Exchange
Market Cap$35.49B$3.48B$6.18B$10.69B
Dividend YieldN/A2.26%5.72%4.83%
P/E Ratio-28.958.2420.7722.98
Price / Sales96.07481.95579.80129.94
Price / CashN/A47.5937.5161.65
Price / Book103.3210.6612.476.59
Net Income-$913.77M-$52.56M$3.32B$276.14M
7 Day Performance2.44%4.97%1.87%0.01%
1 Month Performance14.20%16.48%8.40%3.60%
1 Year Performance128.71%14.95%63.49%32.76%

Insmed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INSM
Insmed
3.0579 of 5 stars
$165.31
-1.5%
$152.88
-7.5%
+125.3%$35.49B$363.71M-28.951,271Analyst Forecast
SNY
Sanofi
4.4184 of 5 stars
$48.80
+1.5%
$62.67
+28.4%
-9.5%$119.83B$44.46B11.7382,878Upcoming Earnings
GSK
GSK
1.8783 of 5 stars
$43.67
+0.3%
$37.38
-14.4%
+14.4%$88.83B$31.63B20.2268,629Dividend Cut
ARGX
argenex
3.2485 of 5 stars
$799.56
+0.3%
$817.53
+2.2%
+50.3%$48.93B$3.05B41.001,599
TAK
Takeda Pharmaceutical
2.5401 of 5 stars
$13.72
+0.0%
N/A-1.8%$43.64B$4.48T45.7247,455
ONC
BeOne Medicines
3.041 of 5 stars
$327.03
+2.2%
$340.30
+4.1%
N/A$35.84B$3.81B-189.0311,000Analyst Forecast
BNTX
BioNTech
2.6813 of 5 stars
$102.30
+0.2%
$134.32
+31.3%
-3.4%$24.59B$2.88B-63.946,772News Coverage
TEVA
Teva Pharmaceutical Industries
3.4852 of 5 stars
$20.02
-0.1%
$25.57
+27.8%
+8.2%$22.96B$16.63B-125.0936,830News Coverage
Positive News
GMAB
Genmab A/S
3.8788 of 5 stars
$32.68
+2.7%
$40.80
+24.8%
+32.9%$20.98B$3.12B16.422,682Positive News
Analyst Downgrade
Short Interest ↑
Analyst Revision
SMMT
Summit Therapeutics
3.0356 of 5 stars
$22.93
+7.4%
$31.29
+36.4%
-5.6%$17.03B$700K-22.70110Trending News
Earnings Report
Analyst Forecast
Options Volume
ASND
Ascendis Pharma A/S
3.0349 of 5 stars
$208.43
-0.5%
$248.29
+19.1%
+58.0%$12.86B$393.54M-40.391,017News Coverage
Analyst Upgrade
Gap Up

Related Companies and Tools


This page (NASDAQ:INSM) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners